ESRD prevalence varied widely by state in 2016, with values of >2,500 per million in the District of Columbia and ≤1,300 per million in Alaska, Vermont, Maine, and New Hampshire.
Chart Explanation: ESRD prevalence varied by state. In 2016, the highest prevalence was found in the District of Columbia (>2,500 per million population); 7 other states also had relatively high prevalence, at >2,100 per million population (Illinois, Missouri, South Dakota, Ohio, Indiana, Wisconsin, and Michigan).
The states with the lowest prevalence of ESRD were New Hampshire (1,146 per million), Vermong (1,155 per million), Alaska (1,142 per million), and Maine (1,256 per million).
Many of the U.S. states have shown minor decreases in prevalence since 2016, particuarly in states with the highest and lowest prevalences. Nonetheless, the Midwest region developed to having consisntently the highest prevalence of ESRD, relative to other regions, with most states having >2,500 per million in the population. In addition, the Southwest region continues to have a high prevalence, but with most states having <2,100 per million prevalence in the population.
The United States Renal Data System (USRDS) is national registry of all patients treated for end-stage renal disease in the United States. It is sponsored by the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) and the Centers for Medicare & Medicaid Services (CMS) that reports prevalence of all treated ESRD in the United States. U.S. population denominators are determined through U.S. Census data. Tables from the USRDS annual report (United States Renal Data System, 2018
) are publicly available for download.
|Description of Measure||Prevalence of end-stage renal disease (ESRD) (Stage 5)|
|Data Source||USRDS (NIDDK/CMS)|
|Type of Data Source||Public|
|Health Care System Data||No|
|Regional or National?||National|
|Demographic Group||Medicare-eligible U.S. citizens with ESRD-related claims with known age, race/ethnicity, and gender|
|Numerator||December 31 point prevalent counts of patients reported to have ESRD without loss-to-follow up or recovery of renal function|
|Denominator||U.S. resident population from U.S. census from corresponding year|
|Definition of CKD||Stage 5, <15 ml/min/1.73 m² with Medicare-eligibility for ESRD-related treatment|
|Primary Data Source Indicator||Number of U.S. patients reported to have ESRD, as indicated by treatment (dialysis or functioning transplant)|
|Primary Indicator Method of Measurement||Claims|
|Frequency of Measurement (Primary)||Annual (cross-sectional)|
|U.S. Region Covered by Primary Variable||All|
|Period Currently Available||2016|
|Additional Data Items of Interest||Year, age (from date of birth), race/ethnicity (from Medicare 2728 form), gender (from Medicare 2728 form), assigned cause of ESRD (from Medicare 2728 form)|
|Limitations of Indicator||Only those who are Medicare-eligible are captured & eligibility may be delayed|
|Analytical Considerations||Denominators change with missing stratification variables|
References and Sources:
United States Renal Data System. 2017 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2017.
United States Renal Data System. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2018.